A best evidence topic in cardiothoracic surgery was written according to a structured protocol. The question addressed was whether gabapentin, a commonly prescribed neuropathic analgesic and anticonvulsant, is safe and beneficial in patients with post-thoracotomy pain following thoracic surgery. Seventeen papers were identified using the search described below, and five papers presented the best evidence to reach conclusions regarding the issues of interest for this review. Side effects and complications as well as evidence of benefit, typically using various pain-scoring systems, were included in the assessment. The author, date and country of publication, patient group studied, study type, relevant outcomes, results and study weaknesses of the papers are tabulated. The systematic review of two randomized controlled trials (RCTs) demonstrated that the use of a single dose gabapentin does not reduce pain scores or the need for epidural or morphine immediately in hospital following thoracic surgery. One double-blinded RCT used multiple doses of gabapentin perioperatively and showed that oral gabapentin administered preoperatively and during the first 2 days postoperatively, in conjunction with patient controlled analgesia morphine, provides effective analgesia in thoracic surgery with a consequent improvement in postoperative pulmonary function and less morphine consumption. One prospective clinical study comparing a 2-month course of gabapentin with naproxen sodium for chronic post thoracotomy pain following surgery showed significant improvement in both the visual analogue scale (VAS) score and the Leeds assessment of neuropathic symptoms and signs (LANSS) at 60 days in the gabapentin (P = 0.001). One prospective study of out-patients with chronic pain (>4 weeks since thoracotomy performed) suggested that gabapentin is effective, safe and well tolerated when used for persistent postoperative and post-traumatic pain in thoracic surgery patients. We conclude that there is no evidence to support the role of a single preoperative oral dose of gabapentin in reducing pain scores or opioid consumption following thoracic surgery. Multiple dosing regimens may be beneficial in reducing acute and chronic pain; however, more robust randomized control studies are needed.
INTRODUCTION
A best evidence topic was constructed according to a structured protocol. This protocol is fully described in the ICVTS [1] . 
THREE PART QUESTION

CLINICAL SCENARIO
The pain team at your hospital discusses with you the introduction of a new perioperative pain management protocol for patients undergoing thoracic surgery. The protocol includes the use of gabapentin. You are not sure whether gabapentin is a safe and effective drug so you decide to to look up the evidence yourself. 
SEARCH STRATEGY
Medline
SEARCH OUTCOME
A total of 17 papers were identified of which 5 were deemed to be relevant (see Table 1 ).
RESULTS
Pain experienced post-thoracic surgery can have a major impact on a patient's mobility and recovery. Many factors can affect the analgesic outcome after thoracic surgery, including surgical 
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technique, choice of analgesic modality, postoperative level of care, ongoing input from acute pain and physiotherapy services and the patient factor. The current evidence base tends towards a multimodal approach to pain control, targeting a range of different pathways and neurotransmitters. Our search identified three randomized control studies that compared the effectiveness of preoperative administration of gabapentin to placebo.
Kinney et al. carried out a prospective, randomized, doubleblinded, placebo-controlled study in adults undergoing elective thoracotomy. Patients were randomly assigned to receive a single dosing regime of 600 mg gabapentin or active placebo orally within 2 h prior to surgery as a one-off dose. Standardized management included thoracic epidural infusion, intravenous patientcontrolled opioid analgesia, acetaminophen and ketorolac. One hundred and twenty patients (63 placebo and 57 gabapentin) were studied. This study revealed that pain scores did not significantly differ at any time point (P = 0.53). Parenteral and oral opioid consumption were not significantly different between groups on postoperative day 1 or 2 (P > 0.05 in both cases). The frequency of side effects such as nausea and vomiting or respiratory depression was not significantly different between groups, but gabapentin was associated with decreased frequency of pruritus requiring treatment with an antihistamine or termination of opiate analgesia (14% gabapentin vs 43% control group, P < 0.001). The frequency of patients experiencing pain at 3 months post-thoracotomy was also comparable between groups (70% gabapentin vs 66% placebo group, P = 0.72). The authors concluded that a single preoperative oral dose of gabapentin did not reduce pain scores or opioid consumption following elective thoracotomy, and did not confer any analgesic benefit in the setting of effective multimodal analgesia that included thoracic epidural infusion. Similar outcomes were reported by Hout et al. in a previous randomized, double-blinded, placebo-controlled study. Omran et al. however, reported that the administration of a single dose of 1200 mg 1 h preprocedure and further 600 mg doses every 12 h post-procedure for 48 h in conjunction with patient controlled analgesia (PCA) morphine provides effective analgesia in thoracic surgery with a consequent improvement in postoperative pulmonary function and less morphine consumption.
Similar results were reported by Solak et al. in a prospective study that used gabapentin for 60 days with an incremental stepwise dosage (300 mg/day for the first 3 days, then 900 mg/day until the 15th day, 1800 mg/day between the 15th and 30th days and finally 2400 mg/day between the 30th and 60th days).
The role of gabapentin in chronic post-thoracic surgery pain management was addressed in a prospective study by Sihoe et al., and suggested that gabapentin is safe and well tolerated when used for persistent postoperative and post-traumatic pain in thoracic surgery patients. This study, however, has many limitations, and the follow-up included only 75% of the patients. The patients enrolled had a wide range of procedures included thoracotomy, VATS, sternotomy and blunt chest trauma. There was no consistent perioperative analgesic protocol and initiation of gabapentin therapy was started at a mean of 5.7 months following surgery.
CLINICAL BOTTOM LINE
There is no evidence to support the role of a single preoperative oral dose of gabapentin in reducing pain scores or opioid consumption following thoracic surgery. Multiple dosing regimens may be beneficial in reducing acute and chronic pain; however, more robust randomized control studies are needed.
